Cellectis (NASDAQ:CLLS) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, Barclays reduced their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Down 0.6 %

Shares of CLLS opened at $1.53 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The company has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $1.91. Cellectis has a 52 week low of $1.41 and a 52 week high of $3.38. The firm has a market capitalization of $85.04 million, a P/E ratio of -1.18 and a beta of 3.06.

Institutional Trading of Cellectis

Several institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in Cellectis in the fourth quarter worth about $962,000. B Group Inc. acquired a new position in shares of Cellectis in the 4th quarter worth approximately $5,547,000. Finally, Wells Fargo & Company MN lifted its position in shares of Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after buying an additional 12,500 shares during the period. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.